Bli medlem
Bli medlem

Du är här


BioGaia: BioGaia's probiotic effective in treating abdominal pain in children

A randomized, double-blind, placebo-controlled study in 93 children
diagnosed with functional abdominal pain showed that L. reuteri
Protectis reduced both frequency and severity of pain compared to

"According to the results, physicians facing the common and
challenging problem of functional abdominal pain in children might
suggest the use of L. reuteri Protectis, as an accessible way to
relieve pain intensity and reduce its frequency", says Professor Zvi
Weizman from the Paediatric Gastroenterology and Nutrition Unit,
Soroka University Medical Center, Faculty of Health Sciences,
Ben-Gurion University, Beer-Sheva, Israel.

After four weeks of intervention the number of pain episodes were
almost halved among the children supplemented with one chewable
tablet per day of L. reuteri Protectis compared to the placebo group.
The severity of pain was also significantly reduced in the probiotic
group compared to placebo and this effect persisted during the
follow-up period.

"Stomach pain is common among children and often affects the child's
daily life through for example anxiety and school absenteeism. It is
therefore very gratifying that this study, which confirms earlier
results with L. reuteri Protectis, shows that BioGaia ProTectis could
offer these children an effective, safe and easy option", says Axel
Sjöblad, Managing Director, BioGaia.

The study was published online in the Journal of Pediatrics
( 4 May 2016. Study facts
and an interview
( with the
principal investigator, Professor Zvi Weizman are found through the
attached links.

Latest press releases from BioGaia
2016-05-11 Annual General Meeting of BioGaia
2016-05-10 BioGaia AB - Interim management statement 1 January - 31
March 2016

2016-05-02 Yet another meta-analysis confirms the effectiveness of
BioGaia's probiotic in infantile colic

BioGaia has published this information in accordance with the Swedish
Securities Market Act. The information was issued for publication on
17 May 2016, 01:00 pm CET.

For additional information please contact
Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00

BioGaia is a healthcare company that develops, markets and sells
probiotic products with documented health benefits. The products are
primarily based on the lactic acid bacterium Lactobacillus reuteri
which has probiotic, health-enhancing effects. The class B share of
the Parent Company BioGaia AB is quoted on the Mid Cap list of NASDAQ
Stockholm main market.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.